Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [1] Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
    Yasenchak, Christopher A.
    Bordoni, Rodolfo
    Patel-Donnelly, Dipti
    Larson, Timothy
    Goldschmidt, Jerome
    Boccia, Ralph V.
    Cline, Vivian J. M.
    Sacchi, Mariana
    Forero-Torres, Andres
    Sims, Robert B.
    Liu, Jingmin
    Friedberg, Jonathan W.
    BLOOD, 2020, 136
  • [2] Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.
    Yasenchak, Christopher A.
    Bordoni, Rodolfo Eduardo
    Patel-Donnelly, Dipti
    Larson, Tim
    Goldschmidt, Jerome H.
    Boccia, Ralph, V
    Cline, Vivian Jean M.
    Forero-Torres, Andres
    Sims, Robert Brownell
    Newhook, Trevor
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
    Forero-Torres, Andres
    Holkova, Beata
    Goldschmidt, Jerome
    Chen, Robert
    Olsen, Gregg
    Boccia, Ralph V.
    Bordoni, Rodolfo E.
    Friedberg, Jonathan W.
    Sharman, Jeff P.
    Palanca-Wessels, Maria Corinna
    Wang, Yinghui
    Yasenchak, Christopher A.
    BLOOD, 2015, 126 (26) : 2798 - 2804
  • [4] Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
    LaCasce, Ann
    Bociek, R. Gregory
    Matous, Jeffrey
    Sawas, Ahmed
    Caimi, Paolo
    Ansell, Stephen M.
    Islas-Ohlmayer, Miguel
    Cheung, Eric
    Agura, Edward
    Behler, Caroline
    Crosswell, Howland
    Vose, Julie M.
    Josephson, Neil
    Advani, Ranjana
    BLOOD, 2014, 124 (21)
  • [5] Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma Who Are Relapsed or Refractory After Frontline Therapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 8 - 10
  • [6] Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study
    Forero-Torres, Andres
    Holkova, Beata
    Sharman, Jeff P.
    Friedberg, Jonathan W.
    Berkowitz, Maurice J.
    Fintel, William
    Chen, Robert
    Boccia, Ralph V.
    Saleh, Mansoor
    Josephson, Neil
    Palanca-Wessels, Maria Corinna
    Yasenchak, Christopher A.
    BLOOD, 2014, 124 (21)
  • [7] Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma
    Younes, Anas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (01) : 27 - +
  • [8] BRENTUXIMAB VEDOTIN-BENDAMUSTINE COMBINATION FOR HODGKIN LYMPHOMA: EXPERIMENT WITH 8 PATIENTS
    Carola, C.
    Dennetiere, S.
    Votte, P.
    Marolleau, J. P.
    Royer, B.
    HAEMATOLOGICA, 2016, 101 : 473 - 474
  • [9] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [10] Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
    Shanbhag, Satish
    Prasad, Vinay
    EUROPEAN JOURNAL OF CANCER, 2018, 104 : 252 - 253
12345